Clinical Trial Update: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant Intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in high-risk stage I non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Intismeran (V940)
• Pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) (Pembrolizumab + berahyaluronidase alfa)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING